The safety and efficacy of anti-PD-1 centrelimab combined with the bi-specific antibody amivantamb are also being tested in patients with NSCLC and driver mutations progressed after TT (phase I) or in patients with EGFR mutations (phase II) (NCT05908734). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.